Skip to main content
Premium Trial:

Request an Annual Quote

Albert Einstein College Wins $1.5M ENCODE Grant to Study Epigenetics

NEW YORK (GenomeWeb News) — The Albert Einstein College of Medicine of Yeshiva University will use a $1.5 million technology grant from the National Human Genome Research Institute to study epigenetic control mechanisms, the college said this week.
The three-year grant, awarded to Einstein Professor of Medicine and Molecular Genetics John Greally, is part of the second phase of the NHGRI’s Encyclopedia of DNA Elements project. It will be carried out with two research partners at the Broad Institute, which was awarded $4.8 million in ENCODE funds earlier this month. 
Greally will work with Brad Bernstein of Massachusetts General Hospital and Andi Gnirke of the Broad Institute to develop assays based on high-throughput sequencing.
The sequencing technology will “allow us to generate billions of base pairs of DNA sequence information in each experiment, allowing us to study the epigenome at a level of resolution that has never previously been possible,” Greally said.
The researchers will study methylation of cytosine and modifications of histones, which can control whether or not genes are switched on or off and whether or not they are expressed.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.